vs
Side-by-side financial comparison of TDH Holdings, Inc. (PETZ) and Scinai Immunotherapeutics Ltd. (SCNI). Click either name above to swap in a different company.
TDH Holdings, Inc. is the larger business by last-quarter revenue ($1.5M vs $773.0K, roughly 1.9× Scinai Immunotherapeutics Ltd.).
TDH Holdings, Inc. is a pet product enterprise that develops, manufactures and distributes a comprehensive portfolio of pet food, nutritional treats, and daily pet supplies for dogs and cats. Its primary market is mainland China, catering to both online e-commerce and offline physical retail customer segments.
PETZ vs SCNI — Head-to-Head
Income Statement — Q2 FY2023 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5M | $773.0K |
| Net Profit | $-1.3M | — |
| Gross Margin | 27.5% | — |
| Operating Margin | -149.8% | — |
| Net Margin | -90.1% | — |
| Revenue YoY | — | 172.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $773.0K | ||
| Q2 24 | — | $284.0K | ||
| Q2 23 | $1.5M | — |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | $-1.3M | — |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | 27.5% | — |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | -149.8% | — |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | -90.1% | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.8M | $989.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $21.2M | $7.9M |
| Total Assets | $36.5M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $989.0K | ||
| Q2 24 | — | $3.1M | ||
| Q2 23 | $31.8M | — |
| Q2 25 | — | $7.9M | ||
| Q2 24 | — | $-7.3M | ||
| Q2 23 | $21.2M | — |
| Q2 25 | — | $11.8M | ||
| Q2 24 | — | $14.9M | ||
| Q2 23 | $36.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-581.1K | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | $-581.1K | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
